Macroporous organosilicon nanocomposites co-deliver Bcl2-converting peptide and chemotherapeutic agent for synergistic treatment against multidrug resistant cancer

Hata, 2015, The BCL2 family: key mediators of the apoptotic response to targeted anticancer therapeutics, Cancer Discov., 5, 475, 10.1158/2159-8290.CD-15-0011 Hanada, 1995, Structure-function analysis of Bcl-2 protein. Identification of conserved domains important for homodimerization with Bcl-2 and heterodimerization with Bax, J. Biol. Chem., 270, 11962, 10.1074/jbc.270.20.11962 Kang, 2009, Bcl-2 inhibitors: targeting mitochondrial apoptotic pathways in cancer therapy, Clin. Cancer Res., 15, 1126, 10.1158/1078-0432.CCR-08-0144 Yoshino, 2006, Bcl-2 expression as a predictive marker of hormone-refractory prostate cancer treated with taxane-based chemotherapy, Clin. Cancer Res., 12, 6116, 10.1158/1078-0432.CCR-06-0147 Shipp, 2002, Diffuse large B-cell lymphoma outcome prediction by gene-expression profiling and supervised machine learning, Nat. Med., 8, 68, 10.1038/nm0102-68 Li, 2000, Cytochrome c release and apoptosis induced by mitochondrial targeting of nuclear orphan receptor TR3, Science, 289, 1159, 10.1126/science.289.5482.1159 Lin, 2004, Conversion of Bcl-2 from protector to killer by interaction with nuclear orphan receptor Nur77/TR3, Cell, 116, 527, 10.1016/S0092-8674(04)00162-X Kolluri, 2008, A short Nur77-derived peptide converts Bcl-2 from a protector to a killer, Cancer Cell, 14, 285, 10.1016/j.ccr.2008.09.002 Gu, 2011, Tailoring nanocarriers for intracellular protein delivery, Chem. Soc. Rev., 40, 3638, 10.1039/c0cs00227e Kumar, 2014, Novel polymeric nanoparticles for intracellular delivery of peptide Cargos: antitumor efficacy of the BCL-2 conversion peptide NuBCP-9, Cancer Res., 74, 3271, 10.1158/0008-5472.CAN-13-2015 Kumar, 2014, Intracellular delivery of peptide cargos using iron oxide based nanoparticles: studies on antitumor efficacy of a BCL-2 converting peptide, NuBCP-9, Nanoscale, 6, 14473, 10.1039/C4NR04504A Xu, 2018, Macroporous silica nanoparticles for delivering Bcl2-function converting peptide to treat multidrug resistant-cancer cells, J. Colloid Interface Sci., 527, 141, 10.1016/j.jcis.2018.05.033 Chen, 2009, Co-delivery of doxorubicin and Bcl-2 siRNA by mesoporous silica nanoparticles enhances the efficacy of chemotherapy in multidrug-resistant cancer cells, Small, 5, 2673, 10.1002/smll.200900621 Meng, 2010, Engineered design of mesoporous silica nanoparticles to deliver doxorubicin and P-glycoprotein siRNA to overcome drug resistance in a cancer cell line, ACS Nano, 4, 4539, 10.1021/nn100690m Wu, 2016, Large pore-sized hollow mesoporous organosilica for redox-responsive gene delivery and synergistic cancer chemotherapy, Adv. Mater., 28, 1963, 10.1002/adma.201505524 Cheng, 2018, Hierarchically self-assembled supramolecular host-guest delivery system for drug resistant cancer therapy, Biomacromolecules, 19, 1926, 10.1021/acs.biomac.7b01693 Chen, 2018, Synergistic lysosomal activatable polymeric nanoprobe encapsulating pH sensitive imidazole derivative for tumor diagnosis, Small, 14 Xu, 2018, Dendrimer-like mesoporous silica nanospheres with suitable surface functionality to combat the multidrug resistance, Int. J. Pharm., 553, 349, 10.1016/j.ijpharm.2018.10.056 Hu, 2017, Celastrol-induced Nur77 interaction with TRAF2 alleviates inflammation by promoting mitochondrial ubiquitination and autophagy, Mol. Cell, 66, 141, 10.1016/j.molcel.2017.03.008 Liu, 2015, A peptide-network weaved nanoplatform with tumor microenvironment responsiveness and deep tissue penetration capability for cancer therapy, Adv. Mater., 27, 5034, 10.1002/adma.201501502 Friedrich, 2009, Spheroid-based drug screen: considerations and practical approach, Nat. Protoc., 4, 309, 10.1038/nprot.2008.226 Li, 2016, Stimuli-responsive clustered nanoparticles for improved tumor penetration and therapeutic efficacy, Proc. Natl. Acad. Sci. U. S. A., 113, 4164, 10.1073/pnas.1522080113 Huang, 2012, Size-dependent localization and penetration of ultrasmall gold nanoparticles in cancer cells, multicellular spheroids, and tumors in vivo, ACS Nano, 6, 4483, 10.1021/nn301282m Zhang, 2005, Complete tumor response following intratumoral 32P BioSilicon on human hepatocellular and pancreatic carcinoma xenografts in nude mice, Clin. Cancer Res., 11, 7532, 10.1158/1078-0432.CCR-05-0400 Kapoor, 2016, Intracellular delivery of peptide cargos using polyhydroxybutyrate based biodegradable nanoparticles: studies on antitumor efficacy of BCL-2 converting peptide, NuBCP-9, Int. J. Pharm., 511, 876, 10.1016/j.ijpharm.2016.07.077 Jiang, 2015, The interplay of size and surface functionality on the cellular uptake of sub-10 nm gold nanoparticles, ACS Nano, 9, 9986, 10.1021/acsnano.5b03521 Shi, 2015, Complete regression of xenograft tumors upon targeted delivery of paclitaxel via pi-pi stacking stabilized polymeric micelles, ACS Nano, 9, 3740, 10.1021/acsnano.5b00929 Zhao, 2013, Near-infrared fluorescence energy transfer imaging of nanoparticle accumulation and dissociation kinetics in tumor-bearing mice, ACS Nano, 7, 10362, 10.1021/nn404782p Chen, 2013, In vivo bio-safety evaluations and diagnostic/therapeutic applications of chemically designed mesoporous silica nanoparticles, Adv. Mater., 25, 3144, 10.1002/adma.201205292 Blanco, 2015, Principles of nanoparticle design for overcoming biological barriers to drug delivery, Nat. Biotechnol., 33, 941, 10.1038/nbt.3330 Lu, 2010, Biocompatibility, biodistribution, and drug-delivery efficiency of mesoporous silica nanoparticles for cancer therapy in animals, Small, 6, 1794, 10.1002/smll.201000538 Urata, 2011, Aqueous colloidal mesoporous nanoparticles with ethenylene-bridged silsesquioxane frameworks, J. Am. Chem. Soc., 133, 8102, 10.1021/ja201779d Yu, 2012, Influence of geometry, porosity, and surface characteristics of silica nanoparticles on acute toxicity: their vasculature effect and tolerance threshold, ACS Nano, 6, 2289, 10.1021/nn2043803